A proposal for interpreting and reporting negative studies.
暂无分享,去创建一个
[1] T C Chalmers,et al. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. , 1978, The New England journal of medicine.
[2] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[3] R. Makuch,et al. Illusion and reality: practical pitfalls in interpreting clinical trials. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. Meier,et al. Statistics and medical experimentation. , 1975, Biometrics.
[5] C. Dunnett,et al. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. , 1977, Biometrics.
[6] M. Soloway,et al. A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group a study , 1983, Cancer.
[7] D. Mandallaz,et al. Comparison of different methods for decision-making in bioequivalence assessment. , 1981, Biometrics.
[8] K C Cain,et al. Charts for the early stopping of pilot studies. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] B. Turnbull,et al. Repeated confidence intervals for group sequential clinical trials. , 1984, Controlled clinical trials.
[10] B. Rosner,et al. Relation of serum vitamins A and E and carotenoids to the risk of cancer. , 1984, The New England journal of medicine.
[11] W C Blackwelder,et al. "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.
[12] W. J. Westlake,et al. Use of confidence intervals in analysis of comparative bioavailability trials. , 1972, Journal of pharmaceutical sciences.
[13] Walter W. Hauck,et al. A new procedure for testing equivalence in comparative bioavailability and other clinical trials , 1983 .